Aspirin

Generic Name: Aspirin

Brand Names: Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala

Drug Type: Small Molecule

Chemical Formula: C_₉H_₈O_₄

CAS Number: 50-78-2

Unique Ingredient Identifier: R16CO5Y76E

Background: Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .
...

Indication: Pain, fever, and inflammation
...

Associated Conditions: Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke

Associated Therapies: Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Clinical Trials

Resistance to Aspirin and/or Clopidogrel Among Patients With PAD.

Phase 4

Completed

Conditions: Intermittent Claudication

Interventions: Drug: Aspirin

First Posted Date: 2005-12-07

Last Posted Date: 2014-01-28

Lead Sponsor: Aalborg University Hospital

Target Recruit Count: 263

Registration Number: NCT00262561

Locations: 🇩🇰
Department of Vascular Surgery, Aalborg Hospital, Aalborg, Denmark

A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients

Phase 2

Terminated

Conditions: Breast Neoplasms

Interventions: Drug: Plavix
Drug: Aspirin

First Posted Date: 2005-12-07

Last Posted Date: 2017-03-15

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 48

Registration Number: NCT00263211

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States

Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Dietary Supplement: ascorbic acid
Drug: arsenic trioxide
Drug: bortezomib
Drug: dexamethasone
Drug: thalidomide
Drug: Aspirin

First Posted Date: 2005-11-24

Last Posted Date: 2013-04-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 5

Registration Number: NCT00258245

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

S.I.F.A. II: Prevention Of Thromboembolic Events In Patients With Nonrheumatic Atrial Fibrillation

Phase 3

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: indobufen
Drug: aspirin

First Posted Date: 2005-10-26

Last Posted Date: 2018-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 1372

Registration Number: NCT00244426

Locations: 🇮🇹
Pfizer Investigational Site, Viterbo, Italy

Effects of ASA on Prostate Tissue

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Drug: Aspirin
Drug: Placebo

First Posted Date: 2005-10-06

Last Posted Date: 2016-05-25

Lead Sponsor: University of Washington

Target Recruit Count: 60

Registration Number: NCT00234299

Locations: 🇺🇸
VA Puget Sound Health Care Service, Seattle, Washington, United States

Post-marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)

Phase 4

Completed

Conditions: Cerebral Infarction

Interventions: Drug: Cilostazol
Drug: Aspirin

First Posted Date: 2005-10-06

Last Posted Date: 2011-06-10

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 2800

Registration Number: NCT00234065

Locations: 🇯🇵
Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan

Japanese Primary Prevention Project With Aspirin

Phase 4

Conditions: Hypertension
Hyperlipidemia
Diabetes Mellitus

First Posted Date: 2005-09-26

Last Posted Date: 2005-09-26

Lead Sponsor: Ministry of Health, Labour and Welfare, Japan

Target Recruit Count: 10000

Registration Number: NCT00225849

Locations: 🇯🇵
Keio University School of Medicine, Tokyo, Japan

APACC Study:Prospective Study on Aspirin Efficacy in Reducing Colorectal Adenoma Recurrence

Phase 3

Terminated

Conditions: Colon Adenomas

First Posted Date: 2005-09-23

Last Posted Date: 2012-06-05

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 300

Registration Number: NCT00224679

Locations: 🇫🇷
Hôpital COCHIN Service d'Hépato-Gastro-Entérologie, Paris, Ile de France, France

Impact of Medical and Surgical Therapy on Functional Mitral Regurgitation

Not Applicable

Completed

Conditions: Heart Diseases
Cardiovascular Diseases
Coronary Disease

First Posted Date: 2005-09-23

Last Posted Date: 2014-02-19

Lead Sponsor: Baylor Research Institute

Target Recruit Count: 250

Registration Number: NCT00224809

Locations: 🇺🇸
Baylor Research Institute, Dallas, Texas, United States

Aspirin for the Prevention of Recurrent Venous Thromboembolism

Phase 2

Conditions: Venous Thromboembolism
Deep Venous Thrombosis
Pulmonary Embolism
Atherosclerosis

First Posted Date: 2005-09-22

Last Posted Date: 2011-08-23

Lead Sponsor: University Of Perugia

Target Recruit Count: 70

Registration Number: NCT00222677

Locations: 🇮🇹
Angiologia - Ospedale di Faenza, Faenza, Italy
🇮🇹
Centro Emofilia e Trombosi - Ospedale Maggiore di Milano IRCCS, Milano, Italy
🇮🇹
Medicina Interna I - Arcispedale S. Maria Nuova, Reggio Emilia, Italy

and more 12 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy